In early February 2026, Haemonetics Corporation reported third-quarter fiscal 2026 results showing lower sales of US$338.97 million year over year but higher net income of US$44.74 million, and issued...
Source LinkIn early February 2026, Haemonetics Corporation reported third-quarter fiscal 2026 results showing lower sales of US$338.97 million year over year but higher net income of US$44.74 million, and issued...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.